Kubo, Hajime
Tanabe Pharma Corporation (Japan)
3 papers on CoChatORCID 0000-0001-5729-1994
Most cited papers
- Verified
Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability
Cao, R., Eriksson, A., Kubo, H., Alitalo, K., Cao, Y., & Thyberg, J. (2004) · Circulation Research
Angiogenesis and VEGF in CancerLymphatic System and Diseases
Cited by 324
- Verified
Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy
Diabetes Treatment and ManagementHeart Failure Treatment and Management
Cited by 140
- Verified
A Homeobox Protein, Prox1, Is Involved in the Differentiation, Proliferation, and Prognosis in Hepatocellular Carcinoma
Shimoda, M., Takahashi, M., Yoshimoto, T., Kono, T., Ikai, I., & Kubo, H. (2006) · Clinical Cancer Research
Hepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology
Cited by 106
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free